Article
Food Science & Technology
Wenchen Yu, Jun Gao, Ruobing Hao, Chenjuan Zhang, Hongwei Liu, Jungang Fan, Jie Wei
Summary: The study investigated the therapeutic effects of Aornia melanocarpa Elliot anthocyanins (AMA) in colitis associated colorectal cancer (CRC) using an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model and the Caco-2 cell line. AMA was found to inhibit cell proliferation, alleviate colorectal damages, reduce inflammation, and downregulate the mTORC1 signaling pathway in CRC, suggesting a potential protective mechanism for CRC involving decreased GLS and SLC1A5 expression. This study provides theoretical support for further research on colorectal cancer and offers a new direction for the prevention and individualized treatment of CRC.
Article
Chemistry, Multidisciplinary
Shikai Liu, Wenting Li, Yangyang Zhang, Jialing Zhou, Yaqian Du, Shuming Dong, Boshi Tian, Linyang Fang, He Ding, Shili Gai, Piaoping Yang
Summary: This study introduces a novel silica-based nanoscintillator for cancer therapy, which generates highly toxic peroxynitrite through low-dosage X-ray boosting to induce nitrosative stress via intracellular protein tyrosine nitration. This strategy not only enhances the efficacy of radiotherapy, but also promotes cell apoptosis through oxygen supply and mitochondrial damage.
Article
Biochemistry & Molecular Biology
Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing, Hubing Shi
Summary: The study identified GRB7-PLK1 as a crucial axis mediating RTKs, resulting in tolerance to MEK inhibitors. Therefore, PLK1 is a promising target for enhancing the clinical treatment of CRC patients with KRAS mutations by synergizing with MEK inhibitors.
Article
Nanoscience & Nanotechnology
Ayimukedisi Yalikong, Xu-Quan Li, Ping-Hong Zhou, Zhi-Peng Qi, Bing Li, Shi-Lun Cai, Yun-Shi Zhong
Summary: The HER2-targeted nanoparticles (TPLNP) drug delivery system has shown significant anti-tumor effects on colon cancer with HER2 overexpression and BRAF mutation in preclinical models, suggesting promising potential for clinical application.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Oncology
Jean Descarpentrie, Marcos J. Arauzo-Bravo, Zongsheng He, Alexia Francois, Alvaro Gonzalez, Patricia Garcia-Gallastegi, Iker Badiola, Serge Evrard, Simon Pernot, John W. M. Creemers, Abdel-Majid Khatib
Summary: This study reveals that the malignant phenotype of colorectal cancer stem cells can be repressed by inhibition of the proprotein convertase Furin, leading to reduced expression of stem cell markers LGR5 and Nanog, as well as dysregulated expression of several calcium regulators. Targeting Furin may provide a potential therapeutic approach for colorectal cancer stem cells.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Xia Ji, Aisheng Dong
Summary: This case report describes the FDG PET/CT findings of a rare renal and postcaval lymph node metastasis from colon cancer, which showed increased FDG uptake and mimicked a primary renal cancer with postcaval lymph node metastasis.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Cell Biology
Shuyi Cen, Kun Liu, Yu Zheng, Jianzhen Shan, Chao Jing, Jiale Gao, Hongming Pan, Zhigang Bai, Zhen Liu
Summary: BRAF mutated colon cancer displays a distinct immune microenvironment characterized by increased stromal cells, immune cell infiltration, and lower tumor purity. High expression levels of immunotherapeutic targets are found in these patients, suggesting potential for checkpoint inhibitors in treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Chemistry, Analytical
Nan Zhang, Ming Gao, Zihan Wang, Jingxian Zhang, Weiqi Cui, Jinjin Li, Xiaolin Zhu, Hang Zhang, Dong-Hua Yangb, Xia Xu
Summary: Curcumin can reverse P-gp-mediated multidrug resistance in colon cancer cells by inhibiting P-gp's ATP-dependent transport activity, increasing the intracellular accumulation of Dox in drug-resistant cells, and regulating various metabolic pathways to ultimately reverse multidrug resistance.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Allison S. Cohen, Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman, Kristen K. Ciombor, Dana Cardin, Cathy Eng, Laura W. Goff, Satya Das, Robert J. Coffey, Jordan D. Berlin, H. Charles Manning
Summary: PET imaging using C-11-glutamine is safe and effective for noninvasively visualizing metastatic colon cancer lesions in multiple organs, providing potential utility for cancer imaging and monitoring treatment response.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Maud T. A. Strous, Ragna L. A. van der Linden, Audrey L. H. M. Gubbels, Timothy K. E. Faes, Koop Bosscha, Carolien M. Bronkhorst, Maryska L. G. Janssen-Heijnen, Adriaan P. de Bruine, F. Jeroen Vogelaar
Summary: This study investigates the value of adding molecular markers and the tumour-stroma ratio (TSR) to conventional histological tumour staging methods. The results suggest that poorly differentiated histology, high TSR, BRAF mutation, and MSI status are significant risk factors for cancer recurrence. Additionally, determining both TSR and BRAF improves the prognostication for disease free survival compared to using BRAF alone, and MSI shows additional value in the prognostication of disease free survival.
MOLECULAR MEDICINE
(2023)
Article
Medicine, General & Internal
Razvan Catalin Popescu, Cristina Tocia, Costel Brinzan, Georgeta Camelia Cozaru, Mariana Deacu, Andrei Dumitru, Nicoleta Leopa, Anca Florentina Mitroi, Anca Nicolau, Eugen Dumitru
Summary: Colorectal cancer is a heterogeneous disease with multiple molecular features, and this study aimed to assess the frequency of microsatellite instability in colon cancer. Results showed that microsatellite instability was found in 16.3% of patients, with MSI-H tumors more common in females and those with a family history of colorectal cancer. Additionally, BRAF mutations were identified in 13.9% of patients and were more often present in MSI tumors.
Article
Biochemistry & Molecular Biology
Iris Car, Antje Dittmann, Olga Vasieva, Luka Bockor, Petra Grbcic, Nikolina Pitesa, Marko Klobucar, Sandra Kraljevic Pavelic, Mirela Sedic
Summary: This study identified ezrin protein as a key factor in acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells. Inhibition of ezrin enhanced the anti-proliferative and pro-apoptotic effects of vemurafenib and inhibited critical signaling pathways. These findings support further exploration of combined BRAF inhibitors and actin-targeting drugs as a potential therapeutic approach in BRAFV600E-mutated cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biology
Iris Car, Antje Dittmann, Marko Klobucar, Petra Grbcic, Sandra Kraljevic Pavelic, Mirela Sedic
Summary: Colorectal cancer is the third most common cancer type worldwide. The management of metastatic colon cancer patients carrying BRAFV600E mutation remains challenging due to poor efficacy of chemotherapy drugs. In this study, an in vitro model of colon cancer cells with BRAFV600E mutation irresponsive to the BRAFV600E inhibitor vemurafenib was developed, and their secretome was analyzed using two proteomics technologies.
Review
Biochemistry & Molecular Biology
Go Woon Kim, Dong Hoon Lee, Yu Hyun Jeon, Jung Yoo, So Yeon Kim, Sang Wu Lee, Ha Young Cho, So Hee Kwon
Summary: Glutamine plays a crucial role in cancer metabolism, with cancer cells consuming excessive amounts for rapid proliferation, especially in poorly vascularized cancers. Glutamine synthetase (GS) is essential in cancer metabolism as the sole enzyme responsible for synthesizing glutamine, which supports nucleotide synthesis. GS exhibits pro-tumoral features by providing glutamine to cancer cells in the tumor microenvironment, enabling cancer cells to maintain sufficient glutamine levels for catabolism, ultimately supporting cancer cell proliferation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Surgery
Tim Beck, Ning Zhang, Akeesha Shah, Sarah Khoncarly, Christopher McHenry, Judy Jin
Summary: This study found that DTC detected on PET is mostly of the papillary type, and these papillary thyroid cancers may be more aggressive than those detected through other means, and more frequently harbor BRAF mutations.
JOURNAL OF SURGICAL RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Isabel Alvarado-Cruz, Mariam Mahmoud, Mohammed Khan, Shilin Zhao, Sebastian Oeck, Rithy Meas, Kaylyn Clairmont, Victoria Quintana, Ying Zhu, Angelo Porciuncula, Hailey Wyatt, Shuangge Ma, Yu Shyr, Yong Kong, Patricia M. LoRusso, Daniel Laverty, Zachary D. Nagel, Kurt A. Schalper, Michael Krauthammer, Joann B. Sweasy
Summary: The study found that long-term treatment with PARP inhibitors induced an inflammatory response in BRCA1 mutant cells, leading to the upregulation of inflammatory genes and activation of the cGAS/STING pathway. In contrast, an increased mutational load was induced in BRCA1-complemented cells treated with a PARP inhibitor.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr
Summary: Cancer-Immu is a comprehensive platform that integrates various omics data and clinical phenotypes to explore immunogenomic connections. It provides easy access to data and helps researchers translate omics datasets into biological insights and clinical applications.
Review
Oncology
Jamie E. Chaft, Yu Shyr, Boris Sepesi, Patrick M. Forde
Summary: Biomarker-informed clinical trials are pushing the treatment of early-stage lung cancer beyond cytotoxic chemotherapy, with the incorporation of targeted and immunotherapies. Adjuvant osimertinib, preoperative chemoimmunotherapy, and adjuvant immunotherapy could improve outcomes for resectable lung cancer patients, and ongoing or planned studies focusing on biomarkers, immunotherapy, and targeted therapy may further enhance survival.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
A. L. Schmidt, C. Labaki, C-Y Hsu, Z. Bakouny, N. Balanchivadze, S. A. Berg, S. Blau, A. Daher, T. El Zarif, C. R. Friese, E. A. Griffiths, J. E. Hawley, B. Hayes-Lattin, V Karivedu, T. Latif, B. H. Mavromatis, R. R. McKay, G. Nagaraj, R. H. Nguyen, O. A. Panagiotou, A. J. Portuguese, M. Puc, M. Santos Dutra, B. A. Schroeder, A. Thakkar, E. M. Wulff-Burchfield, S. Mishra, D. Farmakiotis, Yu Shyr, J. L. Warner, T. K. Choueiri
Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.
ANNALS OF ONCOLOGY
(2022)
Article
Biochemical Research Methods
Qi Liu, Chih-Yuan Hsu, Jia Li, Yu Shyr
Summary: This study developed a statistical method for examining dysregulated ligand-receptor interactions in different conditions, and successfully applied it to the study of important diseases such as COVID-19 infection and pulmonary fibrosis.
Letter
Oncology
Philip C. Mack, Jorge E. Gomez, Ananda M. Rodilla, Juan Manuel Carreno, Chih-Yuan Hsu, Christian Rolfo, Noy Meshulami, Amy Moore, Rachel I. Brody, Jennifer C. King, Jacquelyn Treatman, Sooyun Lee, Ariel Raskin, Komal Srivastava, Charles R. Gleason, Diego de Miguel-Perez, Johnstone Tcheou, Dominika Bielak, Rashmi Acharya, David E. Gerber, Nicholas Rohs, Claudia I. Henschke, David F. Yankelevitz, Viviana Simon, John D. Minna, Paul A. Bunn Jr, Adolfo Garcia-Sastre, Florian Krammer, Yu Shyr, Fred R. Hirsch
Article
Oncology
Yingya Zhao, Yu-Tang Gao, Xianglan Zhang, Alan L. Rockwood, Mark M. Kushnir, Qiuyin Cai, Jie Wu, Jiajun Shi, Qing Lan, Nathaniel Rothman, Yu Shyr, Xiao-Ou Shu, Wei Zheng, Gong Yang
Summary: The study suggests that higher levels of circulating free testosterone and estimated aromatase activity may be associated with lower lung cancer risk in postmenopausal never-smoking women.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Cardiac & Cardiovascular Systems
Matthew R. Alexander, Samuel Hank, Bethany L. Dale, Lauren Himmel, Xue Zhong, Charles D. Smart, Daniel J. Fehrenbach, Yuhan Chen, Nitin Prabakaran, Brian Tirado, Megan Centrella, Mingfang Ao, Liping Du, Yu Shyr, Daniel Levy, Meena S. Madhur
Summary: Research suggests that the Trp encoding allele of rs3184504 may be causal for hypertension and renal dysfunction, in part due to the loss of SH2B3-mediated repression of T cell IL-12 signaling leading to enhanced IFNg production.
CIRCULATION RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
M. Benjamin Shoemaker, Zachary T. Yoneda, Diane M. Crawford, Wendell S. Akers, Travis Richardson, Jay A. Montgomery, Sharon Phillips, Yu Shyr, Pablo Saavedra, Juan C. Estrada, Arvindh Kanagasundram, Sharon T. Shen, Gregory F. Michaud, George Crossley, Christopher R. Ellis, Bjorn C. Knollmann
Summary: This study found no significant difference in AF inducibility between (R)-propafenone and (S)-propafenone at clinically relevant concentrations. The results may be confounded by the high rate of inducible atrial flutter.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Qi Liu, Chih-Yuan Hsu, Yu Shyr
Summary: The rapid growth of spatial omics technologies enables the profiling of genome-wide molecular events at molecular and single-cell resolution. SpaGene, a model-free method, is developed to discover spatial patterns rapidly in large-scale spatial omics studies. It outperforms existing methods in power and scalability, and is able to reconstruct unobserved tissue structures and discover ligand-receptor interactions through colocalization.
Article
Oncology
Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih-Yuan Hsu, Saif Alimohamed, Babar Bashir, Stephanie Berg, Mehmet A. Bilen, Daniel Bowles, Cecilia Castellano, Aakash Desai, Arielle Elkrief, Omar E. Eton, Leslie A. Fecher, Daniel Flora, Matthew D. Galsky, Margaret E. Gatti-Mays, Alicia Gesenhues, Michael J. Glover, Dharmesh Gopalakrishnan, Shilpa Gupta, Thorvardur R. Halfdanarson, Brandon Hayes-Lattin, Mohamed Hendawi, Emily Hsu, Clara Hwang, Roman Jandarov, Chinmay Jani, Douglas B. Johnson, Monika Joshi, Hina Khan, Shaheer A. Khan, Natalie Knox, Vadim S. Koshkin, Amit A. Kulkarni, Daniel H. Kwon, Sara Matar, Rana R. McKay, Sanjay Mishra, Feras A. Moria, Amanda Nizam, Nora L. Nock, Taylor K. Nonato, Justin Panasci, Lauren Pomerantz, Andrew J. Portuguese, Destie Provenzano, Matthew Puc, Yuan J. Rao, Terence D. Rhodes, Gregory J. Riely, Jacob J. Ripp, Andrea Rivera, Erika Ruiz-Garcia, Andrew L. Schmidt, Adam J. Schoenfeld, Gary K. Schwartz, Sumit A. Shah, Justin Shaya, Suki Subbiah, Lisa M. Tachiki, Matthew D. Tucker, Melissa Valdez-Reyes, Lisa B. Weissmann, Michael T. Wotman, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Yuanchu James Yang, Michael A. Thompson, Dimpy P. Shah, Jeremy L. Warner, Yu Shyr, Toni K. Choueiri, Trisha M. Wise-Draper
Summary: This cohort study found that systemic anticancer therapies, especially IO, in the context of baseline immunosuppression, were associated with severe clinical outcomes and the development of cytokine storm in patients with cancer and COVID-19.
Article
Oncology
Eric M. Lander, Katherine C. Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G. Abramson
Summary: This novel study investigates the relationship between HER2 amplification and pathologic complete response (pCR) following neoadjuvant anti-HER2 dual therapy without chemotherapy. The results show a positive association between the HER2/CEP17 FISH ratio and pCR.
Article
Oncology
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso
Summary: A multicenter study evaluated the efficacy of olaparib monotherapy in patients with IDH1/2-mutant gliomas. The study showed that olaparib monotherapy can produce prolonged disease stabilization in patients with grade 2/3 histology, but not in patients with grade 4 histology. This suggests potential clinical benefit of olaparib monotherapy in select populations.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Li-Ching Huang, Lindsey K. Stolze, Hua-Chang Chen, Alexander Gelbard, Yu Shyr, Qi Liu, Quanhu Sheng
Summary: Single-cell sequencing is widely used for studying cellular heterogeneity, and sample multiplexing is an important technique that allows for increased capacity, decreased costs, and minimized batch effects. The crucial step in analyzing multiplexed data is demultiplexing, which assigns cells to individual samples. Accurate demultiplexing is essential to avoid misleading characterization.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Respiratory System
Emily Pei-Ying Lin, Li-Ching Huang, Jennifer Whisenant, Sally York, Travis Osterman, Jennifer Lewis, Wade Iams, Emily Skotte, Amanda Cass, Chih-Yuan Hsu, Yu Shyr, Leora Horn
Summary: This study shows that influenza vaccination (FV) does not increase toxicity for patients with advanced thoracic cancer on immune checkpoint inhibitors (ICIs) and is associated with a decreased risk of grade 3-5 immune-related adverse events (IRAEs). However, FV does not have a statistically significant impact on survival times.
